RxDoctor Payments Data

Maegan Manson

Family · Charleston, SCNPI 1659859361

Payments from drug & device makers

$893in general payments, 2019–2025

Across 10 payments — averaging $89.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BETA Bionics, Inc.$141
  • Corcept Therapeutics$125
  • Abbott$124
  • Lilly USA, LLC$123
  • Merz North America, Inc.$115
  • Sanofi-aventis U.S. LLC$92
  • plus $173 from 3 others

What the payments were for

  • Food & beverage$82893%
  • Education$657%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$893 in reported general payments places this provider in the 65th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$11,457
Medicare patients
71
Services billed
155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide108$130,960
OzempicSemaglutide88$97,237
JardianceEmpagliflozin34$28,782
Humulin R U-500 KwikpenInsulin Regular, Human35$27,235
Tresiba Flextouch U-200Insulin Degludec18$21,534
TrulicityDulaglutide19$18,991
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$16,214
Lantus SolostarInsulin Glargine,hum.Rec.Anlog84$9,738
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$9,666
Tresiba Flextouch U-100Insulin Degludec18$8,942
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$7,411
Humalog Kwikpen U-100Insulin Lispro26$6,996
Insulin Lispro Kwikpen U-100Insulin Lispro23$6,036
FarxigaDapagliflozin Propanediol11$5,737
Nano 2nd Gen Pen NeedlePen Needle, Diabetic50$5,172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$123$149,950127 claims
Novo NordiskOzempic, Novolog$65$100,022101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,248 family providers in South Carolina.

Other family in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →